Navigation Links
Lupus Nephritis Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com
Date:6/10/2015

Dallas, TX (PRWEB) June 10, 2015

The report “Lupus Nephritis – Pipeline Review, H1 2015” provides comprehensive information on the therapeutic development for Lupus Nephritis. Lupus nephritis is kidney inflammation caused by systemic lupus erythematosus. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on Lupus Nephritis with 31 market data tables and 15 figures, spread across 108 pages is available at http://www.rnrmarketresearch.com/lupus-nephritis-pipeline-review-h1-2015-market-report.html .

Companies discussed in this Lupus Nephritis – Pipeline Review, H1 2015 report include AbbVie Inc., Azano Pharmaceuticals Inc., Biogen, Inc., Bristol-Myers Squibb Company, Deltanoid Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., FibroStatin SL, GlaxoSmithKline plc, Invion Limited, Kadmon Corporation, LLC, Millennium Pharmaceuticals, Inc., Teva Pharmaceutical Industries Limited, Zyrnat Biotherapeutics SL.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are abatacept (recombinant), belimumab, BIIB-023, DP-001, Drug to Antagonize Bradykinin Receptor B1 for Lupus Nephritis, FSMAB-26, INV-103, ixazomib citrate, KD-025, laquinimod sodium, Monoclonal Antibody for Lupus Nephritis, P-Dex, RO-5461111, venetoclax, voclosporin, Y-175L, ZY-11.

Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=390976 . (This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases cover by this report includes: Mar 30, 2015: Aurinia Highlights Initiation of Its Open Label Clinical Study to Investigate the Impact of Voclosporin on Lupus Nephritis Biomarkers; Feb 09, 2015: Aurinia Pharmaceuticals to Initiate an Open Label Clinical Study to Investigate the Impact of Voclosporin on Lupus Nephritis Biomarkers; Dec 11, 2014: Kadmon Corporation's KD025 Named a Top Priority Lupus Treatment Candidate by the Alliance for Lupus Research and the Lupus Research Institute; Jun 26, 2014: Aurinia Pharmaceuticals Initiates Phase 2b Clinical Trial of Voclosporin to Treat Lupus Nephritis; May 05, 2014: Possible Treatment for Kidney Disease in Lupus Studied at UH; May 05, 2014: Kadmon Corporation Presents Results of KD025 Preclinical and Clinical Studies at AAI Annual Meeting; Feb 07, 2014: Researchers Exploring Treatment For Lupus-Based Kidney Disease; Oct 15, 2013: Kadmon Announces Development Plans for Selective ROCK 2 Inhibitor, KD025, in Psoriasis, Lupus Nephritis and NASH; Jun 12, 2013: Teva And Active Biotech Report Positive Results From Phase IIa Study Of Laquinimod In Active Lupus Nephritis.

Inquire for Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=390976 . (This is a premium report priced at US$2000 for a single user License.)

List of Tables
Number of Products under Development for Lupus Nephritis, H1 2015 9
Number of Products under Development for Lupus Nephritis - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Products under Development by Companies, H1 2015 16
Products under Investigation by Universities/Institutes, H1 2015 17
Lupus Nephritis - Pipeline by AbbVie Inc., H1 2015 18
Lupus Nephritis - Pipeline by Azano Pharmaceuticals Inc., H1 2015 19
Lupus Nephritis - Pipeline by Biogen, Inc., H1 2015 20
Lupus Nephritis - Pipeline by Bristol-Myers Squibb Company, H1 2015 21
Lupus Nephritis - Pipeline by Deltanoid Pharmaceuticals Inc., H1 2015 22
Lupus Nephritis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 23
Lupus Nephritis - Pipeline by FibroStatin SL, H1 2015 24
Lupus Nephritis - Pipeline by GlaxoSmithKline plc, H1 2015 25
Lupus Nephritis - Pipeline by Invion Limited, H1 2015 26
Lupus Nephritis - Pipeline by Kadmon Corporation, LLC, H1 2015 27
Lupus Nephritis - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 28
Lupus Nephritis - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 29
Lupus Nephritis - Pipeline by Zyrnat Biotherapeutics SL, H1 2015 30
Assessment by Monotherapy Products, H1 2015 31
Number of Products by Stage and Target, H1 2015 33
Number of Products by Stage and Mechanism of Action, H1 2015 35
Number of Products by Stage and Route of Administration, H1 2015 37
Number of Products by Stage and Molecule Type, H1 2015 39
Lupus Nephritis Therapeutics - Recent Pipeline Updates, H1 2015 74
Lupus Nephritis - Dormant Projects, H1 2015 98
Lupus Nephritis - Dormant Projects (Contd..1), H1 2015 99
Lupus Nephritis - Discontinued Products, H1 2015 100

Explore more reports on Renal therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/kidney/kidneyrenal-therapeutics .

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Read the full story at http://www.prweb.com/releases/lupus-nephritis-pipeline/review-h1-2015-market/prweb12779381.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related medicine news :

1. 9th Annual Walk to End Lupus Now
2. Drug Combo Helps Lupus-Related Kidney Condition
3. NIH announces network to accelerate medicines for rheumatoid arthritis and lupus
4. Math model designed to replace invasive kidney biopsy for lupus patients
5. Certain Symptoms Can Delay Lupus Diagnosis, Researchers Report
6. Rheumatologic diseases like lupus can initially look like neurological disorders
7. Lupus Patients Face High Rehospitalization Rates
8. One in 6 lupus patients readmitted to hospital within 30 days of discharge
9. In the quest for safer treatment for systemic lupus erythematosus
10. Anti-dsDNA, surface-expressed TLR4 and endosomal TLR9 cooperate to exacerbate lupus
11. EpiCast Report: Systemic Lupus Erythematosus Epidemiology Forecast to 2022
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... ... A Child” is the creation of published author, Pauline DiBenedetto. , “As my mother was ... in such great pain, my mother thought that her time has come. Once I was ... was about eight years old, when I had a vision of my own, that my ...
(Date:8/15/2017)... , ... August 15, 2017 , ... ... announced at his Inauguration that WesternU will move forward in bold new directions ... , WesternU combined Wilson’s Inauguration ceremony with Convocation, the traditional opening of the ...
(Date:8/15/2017)... ... 2017 , ... The Philadelphia Marathon and the American Association for Cancer Research ... the City’s commitment to improving the health of its citizens. Dedicated to preventing and ... healthy lifestyle as research shows this can help reduce the risk of cancer. ...
(Date:8/15/2017)... ... 2017 , ... Progressive Dental, a leading dental marketing and consulting ... list of Fastest Growing Companies in Tampa Bay. The Tampa Bay Business Journal creates ... consecutive years of growth. For this year’s award, Progressive Dental ranked number 29, with ...
(Date:8/15/2017)... ... August 15, 2017 , ... Dr. Richard Amato is raising ... as a periodontist in Monroe, CT since 1989, Dr. Amato understands that ... is educating his community on how to choose the right clinician for their periodontal ...
Breaking Medicine News(10 mins):
(Date:7/31/2017)...  Diplomat Pharmacy, Inc. (NYSE: DPLO), has been named one ... by Crain,s Detroit Business . The annual ... three-year revenue growth. This year,s edition measures growth from 2013 ... the complete list, visit crainsdetroit.com/awards/fast_50/2017 .  ... said Phil Hagerman , CEO and chairman of Diplomat. ...
(Date:7/28/2017)... 28, 2017 EnvoyHealth, a Diplomat company, has partnered ... for CleverCap LITE, a technology designed to improve patient ... innovative health technology solutions and services that help track ... CleverCap LITE offers medication monitoring and control ... Records date and ...
(Date:7/26/2017)... Medical Aesthetics, a leading medical aesthetic clinic in Singapore ... several skin conditions from the inside. The natural process ... The skin becomes more transparent due to the thinning of the ... from the sun contributes to aging skin, causing age spots and ... ...
Breaking Medicine Technology: